8-K filing — XOMA Royalty Holdings Corp

Autodesk Q2 Adj. EPS $3.30 Beats $3.12 Estimate, Sales $2.046B Beat $2.012B Estimate

Autodesk (NASDAQ:ADSK) reported quarterly earnings of $3.30 per share which beat the analyst consensus estimate of $3.12 by 5.77 percent. This is a 25.95 percent increase over earnings of $2.62 per share from the same

Autodesk Sees Q3 GAAP EPS $1.57-$1.87 vs $2.16 Est

Autodesk (NASDAQ:ADSK) is looking for Q3 GAAP EPS of $1.57-$1.87 vs $2.16 analyst estimate..

Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days

Why Nutanix Stock Is Soaring Today

Nutanix stock surged 9.87% after reporting Q4 2026 results that beat analyst expectations with $757.1 million in revenue (16% YoY growth) and $0.60 diluted EPS versus $0.49 expected. The company also generated strong free cash flow of $277.6 million and provided optimistic fiscal 2027 guidance of $3.18-$3.23 billion in revenue and $850-$950 million in free cash flow.

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

Will Lululemon (LULU) Beat Estimates Again in Its Next Earnings Report?

Lululemon has demonstrated a strong track record of beating earnings estimates, with an average surprise of 3.22% over the last two quarters. The company has a positive Earnings ESP of +0.70% combined with a Zacks Rank #3 (Hold), suggesting a high probability of another earnings beat in its September 3, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time.